Strong earnings have traders eyeing these stocks

👉 Limited Seats Remain in SAJ                                                                                                                                                                                                                                                                                                                                                                                                                 August 15, 2024 | [Read Online]( 👉 Limited Seats Remain in SAJ Good day, 360! Here are our top investing ideas today. And don’t forget to join us in [Market Masters]( - the hottest trading room around 🔥. Be the best prepared trader on the Street! FOCUS LIST🔎 AISP - Up over 25% in pre after reporting better than expected earnings BLRX - Up over 7% in pre after reporting better than expected earnings ARAY - Up over 20% in pre after reporting better than expected earnings 🎯Are you on the list for Jeff’s next Bullseye of the Week? Here’s what a pretty “typical” week looks like: *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. 💥Day 1: Trading plan released pre-market, quick move on Pick of the Week CVNA - alerted members when I was IN and OUT! 🫰Day 2: Would have seen MORE profits if I held… 💨Day 3 on: Would have seen ALL profits VANISH Use discipline, plan your trade and trade your plan. [Get in with all the ACTION – next pick drops Monday!]( HOTLIST🔥 AISP - Up over 25% in pre after reporting better than expected earnings Airship AI Holdings Inc. (AISP) offers Artificial Intelligence driven video, sensor, and data management surveillance platform in the United States. In the after-hours yesterday, the [company announced]( Q2 2024 financial results. Highlights include: Strong Second Quarter 2024 Net Revenues of $6.4 Million, Gross Profit of $4.5 Million and Gross Margin of 70% Second Quarter Operating Income of $1.0 Million Represents Significant Progress Towards Full Year Cash Flow Positive Objective First Half 2024 Combined Net Revenue of $17.0 Million Represents 128% of the Company’s Full Year Revenue in 2023  2024 Outlook Triple-digit revenue growth and positive cash flow for calendar year 2024 supported by a strong and growing validated pipeline of ~$150 million, rapidly improving gross profit margins, and a strong recurring revenue model. Release new Outpost AI product offerings as well as expand custom trained AI models supporting emerging edge analytic workflows. The stock traded up over 25% in the pre-market in reaction to the positive financial results and outlook. The first target for bulls is the pre-market high at $3.69. Beyond that, $4.20, $4.80 and $5.20 come into play. Below $3.69, targets to the downside are $3.20, $3, $2.85, $2.60 and then a gap fill at $2.52. BLRX - Up over 7% in pre after reporting better than expected earnings BioLineRx Ltd. (BLRX) is a commercial stage biopharmaceutical company that develops and commercializes therapeutics for oncology and rare diseases. In the pre-market this morning, the [company reported]( Q2 financial results with corporate and portfolio updates. Highlights include: Total revenue for the three months ended June 30, 2024 was $5.4 million. The Company did not record any revenue during the second quarter of 2023. Revenue for the quarter reflects a portion of the upfront payment from the Gloria Biosciences license, which amounted to $3.6 million, as well as $1.8 million of net revenue from product sales of APHEXDA in the U.S. Net income for the three months ended June 30, 2024 was $0.5 million, compared to net loss of $18.5 million for the same period in 2023. As of June 30, 2024, the Company had cash, cash equivalents, and short-term bank deposits of $40.1 million. The Company anticipates that this amount will be sufficient to fund operations, as currently planned, into 2025 Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - Doubled the number of centers ordering APHEXDA during the second quarter Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease. The first target for bulls is the pre-market high at $0.84. Beyond that, $0.88, $0.93, $1 and then $1.10 come into play. Below $0.84, targets to the downside are $0.80 and then a gap fill at $0.7750 with $0.72 below that.  It’s what you’ve been waiting for… [60% off Small Account Journey -]( [Limited Seats Remain]( Who knew you could burn calories sitting at a computer? Join Jason and his gang as he works his rear off to teach you everything the knows about options selling - all levels welcome ARAY - Up over 20% in pre after reporting better than expected earnings Accuray Incorporated (ARAY) designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States and internationally. In the after-hours yesterday, the [company reported]( Q4 2024 financial results. Highlights include: Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year. GAAP net income of $3.4 million, as compared to GAAP net loss of $2.6 million in the same period in the prior fiscal year. Adjusted EBITDA was $10.1 million in the fourth quarter of fiscal 2024 compared to $5.2 million in the same period in the prior fiscal year. Gross orders of $95.5 million, increased 7.9 percent from the same period in the prior fiscal year. The book to bill ratio was 1.2 in the fourth quarter of fiscal 2024, compared to a book to bill ratio of 1.4 in the same period in the prior fiscal year. Fiscal Year 2025 Financial Guidance - Total revenue is expected in the range of $460 million to $470 million. - Adjusted EBITDA is expected in the range of $27.5 million to $29.5 million. The stock traded up over 20% in reaction to the positive financial results and 2025 guidance. The first target to the upside is prior resistance at $1.85 and then the after-hours high at $1.90. Beyond that, $2.05, $2.20 and $2.40 come into play. Below $1.85, targets to the downside are $1.77, $1.66, $1.55, and then a gap fill at $1.43. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](